Drug Patent Watch
MARCH 5, 2025
The Future of Diabetes Care: How Biosimilar Insulin Products Are Revolutionizing Treatment As we continue to navigate the ever-evolving landscape of diabetes care, one thing is clear: innovation is key. And when it comes to insulin therapy, a game-changing trend is emerging: biosimilar insulin products.
STAT
SEPTEMBER 23, 2022
Market share is often held up as the most relevant metric for the success of a biosimilar class. I believe there are other metrics, like cost savings or signs of greater patient access, that should also be used to define biosimilars’ successes or failures. the first biosimilar was launched in September 2015. In the U.S.,
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Patent Watch
JANUARY 13, 2025
Biosimilars have emerged as a game-changing force, promising to revolutionize patient access to life-saving biologics while simultaneously reducing healthcare costs. ”[1] The global biosimilars market is experiencing exponential growth, with projections indicating it will reach $69.4 billion by 2025, growing at a CAGR of 34.2%
STAT
NOVEMBER 18, 2022
The first therapy that delays the onset of type 1 diabetes received approval from the U.S. million people have type 1 diabetes in the U.S., according to the American Diabetes Association, including 244,000 children and adolescents. Type 1 affects 8% of everyone with diabetes. Food and Drug Administration , CNN tells us.
Express Pharma
NOVEMBER 9, 2023
USV and Biogenomics announced the launch of INSUQUICK, biosimilar Insulin Aspart. Insuquick will be available in cartridges, vials, and prefilled disposable pens, offering flexibility tailored to the needs of people with diabetes. It is available in all metros, and Tier I/II cities.”
STAT
APRIL 4, 2024
… The booming class of GLP-1 drugs that includes Ozempic and Wegovy is not only effective for diabetes and obesity, but is also showing early potential to help with conditions involving the brain, such as mental health disorders, Alzheimer’s, and even, as new study results suggest — Parkinson’s disease , STAT writes. In
STAT
JANUARY 4, 2024
… Starting April 1, CVS Health will no longer offer AbbVie’s Humira to patients in its commercial prescription plans and, instead, will direct them to biosimilar versions of the anti-inflammatory drug that became available last year , Bloomberg News writes.
Expert insights. Personalized for you.
52 
Let's personalize your content